1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

NASH Drug Cost Concerns On Level With HCV Treatments For Payers

 
• By Cathy Kelly

OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.

Drugs in development for non-alcoholic steatohepatitis (NASH) threaten the same kind of cost burden to payers as have the newer hepatitis C drugs, according to OptumRx Inc. Pipeline and Drug Surveillance Manager Farrah Wong.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America